Per Stål
Per Stål
Docent i gastroenterologi, Karolinska Institutet
Verifierad e-postadress på
Citeras av
Citeras av
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
M Ekstedt, H Hagström, P Nasr, M Fredrikson, P Stål, S Kechagias, ...
Hepatology 61 (5), 1547-1554, 2015
Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up
C Söderberg, P Stål, J Askling, H Glaumann, G Lindberg, J Marmur, ...
Hepatology 51 (2), 595-602, 2010
Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives
M Elmberg, R Hultcrantz, A Ekbom, L Brandt, S Olsson, R Olsson, ...
Gastroenterology 125 (6), 1733-1741, 2003
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
H Hagström, P Nasr, M Ekstedt, U Hammar, P Stål, R Hultcrantz, ...
Journal of hepatology 67 (6), 1265-1273, 2017
A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C–associated liver cirrhosis
S Aleman, N Rahbin, O Weiland, L Davidsdottir, M Hedenstierna, N Rose, ...
Clinical infectious diseases 57 (2), 230-236, 2013
Classification criteria for spondyloarthropathies
O Akgul, S Ozgocmen
World Journal of Orthopedics 2 (12), 107, 2011
Liver fibrosis in non-alcoholic fatty liver disease-diagnostic challenge with prognostic significance
P Stål
World Journal of Gastroenterology: WJG 21 (39), 11077, 2015
Iron increases ethanol toxicity in rat liver
P Stål, R Hultcrantz
Journal of hepatology 17 (1), 108-115, 1993
Mild iron overload in patients carrying the HFE S65C gene mutation: a retrospective study in patients with suspected iron overload and healthy controls
P Holmström, J Marmur, G Eggertsen, M Gåfvels, P Stål
Gut 51 (5), 723-730, 2002
Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics
S Wahlin, Y Floderus, P Stål, P Harper
Journal of internal medicine 269 (3), 278-288, 2011
Biliary dysplasia, cell proliferation and nuclear DNA‐fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma
A Bergquist, H Glaumann, P Stål, GS Wang, U Broome
Journal of internal medicine 249 (1), 69-75, 2001
Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long‐term follow‐up study
H Hagström, P Nasr, M Ekstedt, U Hammar, P Stål, R Hultcrantz, ...
Hepatology communications 2 (1), 48-57, 2018
Iron as a hepatotoxin
P Stål
Digestive Diseases 13 (4), 205-222, 1995
Digital ambulatory monitoring of small-bowel motility
G Lindberg, M Iwarzon, P Stål, R Seensalu
Scandinavian journal of gastroenterology 25 (3), 216-224, 1990
Quantitative determination of 8-hydroxy-2′-deoxyguanosine in human urine by isotope dilution mass spectrometry: normal levels in hemochromatosis
I Holmberg, P Stål, M Hamberg
Free Radical Biology and Medicine 26 (1-2), 129-135, 1999
Overweight in late adolescence predicts development of severe liver disease later in life: a 39 years follow-up study
H Hagström, P Stål, R Hultcrantz, T Hemmingsson, A Andreasson
Journal of hepatology 65 (2), 363-368, 2016
Gastroesophageal reflux in healthy subjects: significance of endoscopic findings, histology, age, and sex
P Stål, G Lindberg
Scandinavian journal of gastroenterology 34 (2), 121-128, 1999
The effects of dietary iron on initiation and promotion in chemical hepatocarcinogenesis
P Stål, R Hultcrantz, L Möller, LC Eriksson
Hepatology 21 (2), 521-528, 1995
Liver transplantation for erythropoietic protoporphyria in Europe
S Wahlin, P Stal, R Adam, V Karam, R Porte, D Seehofer, BK Gunson, ...
Liver Transplantation 17 (9), 1021-1026, 2011
Hepatotoxicity induced by iron overload and alcohol: studies on the role of chelatable iron, cytochrome P450 2E1 and lipid peroxidation
P Stål, I Johansson, M Ingelman-Sundberg, K Hagen, R Hultcrantz
Journal of hepatology 25 (4), 538-546, 1996
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20